News

The breakthrough preclinical study demonstrated that highly optimized dMAbs targeting mouse CTLA-4 protein can be robustly expressed in vivo, and shrank tumors in mice. More importantly, Inovio’s dMAb

Chronocort was not successful in confirming its superiority over conventional treatment in endocrine control over a 24-hour period during the late-stage clinical trial held in Europe. Diurnal Group

The regulators have accepted the firm’s filings for investigational oral and once-daily siponimod to treat secondary progressive multiple sclerosis (SPMS) in adults. Siponimod is an investigational and selective

The two studies are projected to deliver a total of c.£9m in revenue, with most of the revenue being recognised in 2019. These contracts are in addition to

The company, founded with seed funding from SV Health investors, raised a total of $30 million from a syndicate of specialist international healthcare investors co-led by SV Health

Merck’s supplemental application has been approved to expand the use of Gardasil 9, which helps in preventing certain cancers and diseases caused by the nine HPV types covered

Hemlibra is now the only prophylactic treatment for people with haemophilia A with and without factor VIII inhibitors that can be administered subcutaneously (under the skin) and at

Merck has announced the first presentation of data from the Phase 3 DRIVE-SHIFT trial evaluating a switch of medication to Delstrigo , a once-daily fixed-dose combination tablet of

Empagliflozin was evaluated for its efficacy, safety and tolerability as an adjunctive to insulin in comparison to placebo in the late-stage clinical program, dubbed EASE. The primary efficacy